Navigation Links
For Moderate to Severe Psoriasis, Thought Leaders' Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
Date:6/24/2013

BURLINGTON, Mass., June 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists in the United States and Europe agree that a drug's effect on psoriatic plaques at 12-16 weeks is one of the attributes that most influences their prescribing decisions in moderate to severe psoriasis. Clinical data and the opinions of interviewed thought leaders indicate that the emerging biologics with novel mechanisms of action that target IL-17 have the potential to offer improvements over sales-leading adalimumab (AbbVie/Eisai's Humira) on this attribute.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase report entitled Which Clinical Attributes Will Most Effectively Position Emerging Agents Against the Market Leader, Adalimumab? also finds that surveyed U.S. and European dermatologists and U.S. managed care organization (MCO) pharmacy directors consider therapies with a lower risk of serious infections than current therapies to be one of the greatest unmet needs in moderate to severe psoriasis. Interviewed thought leaders do not believe any emerging therapy has yet demonstrated clear potential to fulfill this unmet need. However, they are optimistic that agents with more-targeted mechanisms of action, including the IL-17 inhibitors, may offer improved safety compared to those that target multiple molecules or molecules that affect multiple downstream pathways.

The findings also reveal that more MCO pharmacy directors are willing to grant favorable formulary status to therapies that offer improvements in safety compared to the number who would grant this status to agent
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
2. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
3. Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimers Disease
4. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
5. AG Mednet CEO Abraham Gutman to Moderate Disruptive Technologies Session at CenterWatch Forum on Optimizing Clinical Research Performance
6. Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost
7. Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis
8. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
9. New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA
10. Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases
11. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Mass. , March 27, 2015 ... platform for drug discovery and development services which ... for the pharmaceutical industry, announced financial results for ... Timothy C.  Tyson, Chairman of XRpro Sciences ... to successfully transition from development stage to commercial ...
(Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
(Date:3/27/2015)... , March 27, 2015 The International ... of myeloma patients while working toward prevention and a ... (D-NY) for introducing a federal resolution (H. Res. 174) ... 2015 as "National Multiple Myeloma Awareness Month." ... myeloma worldwide, and more than 110,000 new cases are ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... 21 /PRNewswire/ Terumo Heart, Inc. today,announced the discharge of ... Assist System (LVAS). The patient was,discharged home on August ... after receiving the device., The patient is a ... heart failure for nearly 20 years. He is the ...
... have a study,that is falling behind with recruitment? Have ... media but still have not seen the,desired results? Perhaps ... to help,your sites navigate the world of media placements ... Argonauta Assist(TM) service," says Ms. Ann Kottcamp,President of Argonauta ...
Cached Medicine Technology:Discharge of First U.S. DuraHeart(TM) Patient 2Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts 2
(Date:3/28/2015)... Omaha, NE (PRWEB) March 28, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the Ohio Physical Therapy Association Annual ... the Renaissance Columbus Downtown Hotel in Columbus, OH. ... programming, networking opportunities, and exhibits with products and ...
(Date:3/28/2015)... The "Petrick Sustainable Health System" ... After 18 years of research and experience with patients ... Dr. Jon Petrick is excited to be launching his ... the immediate benefits of this radical new system are ... strength of the immune system, faster healing of injuries, ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness Celebration on ... Center in Chesapeake, Virginia. Each year, ARDX celebrates Women’s ... the Hampton Roads region. The 2015 Women’s History Month ... grow stronger through sharing their stories and learning the strategies ... theme is T-talk where we will share a cup of ...
(Date:3/28/2015)... March 28, 2015 Servpro of ... this week released a report about the link between ... asthma sufferers, and according to recent medical research, may ... According to the Environmental Protection Agency, people with sensitivity ... Breathing in mold may trigger asthma attacks for asthma ...
(Date:3/27/2015)... 27, 2015 The Monogamy Method ... experts Samantha Sanderson and Jason Rogers has just been ... media attention. The commotion surrounding the course's launch has ... to publish an in-depth review of the new program. ... men in their lives suddenly start pulling away or ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2
... drug resistance after the failure of an anti-HIV drug combination ... CD4 cell losses, according to a study of patients failing ... ,However, the study also found that on average, patients who ... the choice still available to them for every six months ...
... Johnson and Johnson, manufacturers of Listerine Agent Cool Blue ... tests showed that it contained microorganisms. , ,No ... reported yet. Many outlets have stocked this brand. The ... problem and the public has been cautioned against using ...
... identified and cloned a rice gene that influences rice ... higher yielding varieties of the world's most important food ... genetic mechanisms that determine yield and seed weight in ... past decade. ,In a study published this ...
... of the rainbow nation South Africa, has resulted in ... its own versions of low-cost generic drugs for the ... Diallo, chief pharmacist in the A.U. commission's medical services ... capacity to produce drugs to treat HIV/AIDS, malaria and ...
... America dream-this may be the epitome of many rags- ... at neck-break speed,// takes its pound of flesh too. ... all hospital stays in the U.S are for those including various ... Says the Agency for Research Healthcare and Quality (ARHQ) which released ...
... majority" of elderly people will soon be living in the ... UN agency says citing// India and China as notable examples ... rapidly ageing population can no longer be considered to be ... official said here Wednesday. ,"Many developing nations are ...
Cached Medicine News:Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 3Health News:Scientists Find Rice Gene for Grain Size and Yield 2Health News:Africa Challenged To Produce Its Own Generic Drugs 2Health News:‘Land Of Dreams’ Staggers Under The Weight Of Neuroses And Substance Abu 2Health News:‘Land Of Dreams’ Staggers Under The Weight Of Neuroses And Substance Abu 3
Easy to use , Allow for a flexible washing , Uniform and efficient , Very robust and reliable , Adjustable to all well shapes , Rack included (not autoclavable) , Autoclavable at 121C , No e...
... with a 25-microplate capacity ... and aspiration and dispense ... On-board software for user ... programs. External vacuum pump ...
... available to handle multiple assays: ... Embla 384 Cell washer has ... optimized to avoid cell disturbance. ... and have been integrated with ...
ELISA Microplate Washer, Manual...
Medicine Products: